Intellia Therapeutics (38I) Price & Analysis

Compare

13 Followers

38I Stock Chart & Stats

€12.38

-€0.50(-4.02%)

At close: Jan 08 4:00 PM EST

€12.38

-€0.50(-4.02%)

Day’s Range― - ―

52-Week Range€5.30 - €24.34

Previous CloseN/A

Volume0.00

Average Volume (3M)504.00

Market Cap

€1.36B

Enterprise Value€1.52B

Total Cash (Recent Filing)€511.04M

Total Debt (Recent Filing)€97.97M

Price to Earnings (P/E)―

Beta1.70

Next Earnings

Feb 19, 2026

EPS Estimate

-0.81

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.77

Shares Outstanding115,829,926

10 Day Avg. Volume1,288

30 Day Avg. Volume504

Financial Highlights & Ratios

PEG Ratio0.71

Price to Book (P/B)1.32

Price to Sales (P/S)19.91

P/FCF Ratio-3.25

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€12.01

Price Target Upside-2.98% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering19

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Durable Efficacy And DemandStrong long-term durability signals for the HAE candidate combined with rapid enrollment indicate meaningful commercial demand and potential to replace chronic prophylactic treatments.

HAE Trial ProgressFull enrollment of the Phase III HAE study and RMAT designation support an accelerated regulatory filing pathway for a one-time hereditary angioedema therapy.

Regulatory EngagementOngoing engagement with regulators to resolve the clinical trial hold could enable a restart of pivotal studies and preserve the pathway to approval.

Bears Say

Clinical Hold And FatalityA patient death linked to the ATTR-CM program and the ensuing clinical hold raise regulatory scrutiny and increase uncertainty around development timelines.

Commercial And Payer ChallengesHigh upfront pricing for an irreversible gene-editing therapy and a crowded field of safe alternatives increase the risk of payer pushback and slower market uptake.

Liver Safety RiskLiver injury signals tied to the TTR program, including a Hy’s Law trigger, create significant safety concerns that will require further evaluation and could restrict use.

Intellia Therapeutics News

Intellia Therapeutics announces FDA lift of clinical hold on MAGNITUDE-2 trial

Intellia Therapeutics (NTLA) announced that the U.S. Food and Drug Administration has removed the clinical hold on the...

38m ago

NTLA

Cathie Wood’s ARK Adds to Intellia Stock (NTLA) — Here’s What Else It Traded This Week

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made just one trade on Thursday, January 15, according to its daily...

11d ago

NTLA

Cathie Wood’s ARK Investment buys 57K shares of Intellia Therapeutics today

20:39 EST Cathie Wood’s ARK Investment buys 57K shares of Intellia Therapeutics (NTLA) today Published first on TheFly...

12d ago

NTLA

Cathie Wood Keeps Loading Up on This Biotech Stock — What’s Driving the Buying Spree?

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) continued to buy shares of Intellia Therapeutics ($NTLA) on Tuesday, extending a...

13d ago

NTLA

Cathie Wood’s ARK Investment buys 40K shares of Intellia Therapeutics today

20:01 EST Cathie Wood’s ARK Investment buys 40K shares of Intellia Therapeutics (NTLA) today Published first on TheFly...

14d ago

NTLA

Cathie Wood Doubles Down on High-Potential Biotech Plays

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made notable portfolio moves on Monday, January 12, as revealed in daily fund...

14d ago

TER

TXG

NTLA, PSNL, KMTUY, ILMN: Cathie Wood Buys Early Biotech Stocks, Cuts Stakes in Illumina

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several portfolio moves across biotech and industrial names on Friday, January 9, 2026....

15d ago

ILMN

NTLA

Intellia Therapeutics price target lowered to $12 from $14 at BofA

BofA lowered the firm’s price target on Intellia Therapeutics (NTLA) to $12 from $14 and keeps a Neutral...

21d ago

NTLA

Cathie Wood Closes Out 2025 with a Rocket Lab (RKLB) Trim and Fresh Biotech Bets

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several portfolio moves across biotech and growth stocks on Tuesday, December 30,...

27d ago

BEAM

IONS

Synopsys, Reddit, Intellia, Symbotic, Seagate Insider Shock

Insiders have been trading these 5 stocks: (($SNPS)), (($RDDT)), (($NTLA)), (($SYM)) and (($STX)). Here is a breakdown of...

17d ago

STX

SYM

Balancing Promise and Uncertainty: Justifying a Hold on Intellia Ahead of Key Late‑Stage Readouts

William Blair analyst Myles Minter has reiterated their neutral stance on NTLA stock, giving a Hold rating today....

18d ago

NTLA

Intellia Updates Investors on Nex-Z Trial Safety Hold

Intellia Therapeutics ( ($NTLA) ) just unveiled an update. On January 9, 2026, Intellia Therapeutics updated its corporate...

18d ago

NTLA

Citizens JMP healthcare analysts hold an analyst/industry conference

Healthcare Analysts discuss regulatory landscape for AAV-based gene therapies (relevant companies (SLDB, TSHA, BNTC, SRPT, QURE, NTLA, CRSP,...

2M ago

BNTC

CRSP

Algonquin, Spotify, Keysight, Intellia, CoreWeave: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($AQN) ), ( ($SPOT) ), ( ($KEYS) ), ( ($NTLA)...

2M ago

AQN

CRWV

38I FAQ

What was Intellia Therapeutics’s price range in the past 12 months?

Intellia Therapeutics lowest stock price was €5.30 and its highest was €24.34 in the past 12 months.

What is Intellia Therapeutics’s market cap?

Intellia Therapeutics’s market cap is €1.36B.

When is Intellia Therapeutics’s upcoming earnings report date?

Intellia Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 23 days.

How were Intellia Therapeutics’s earnings last quarter?

Intellia Therapeutics released its earnings results on Nov 06, 2025. The company reported -€0.775 earnings per share for the quarter, beating the consensus estimate of -€0.846 by €0.072.

Is Intellia Therapeutics overvalued?

According to Wall Street analysts Intellia Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Intellia Therapeutics pay dividends?

Intellia Therapeutics does not currently pay dividends.

What is Intellia Therapeutics’s EPS estimate?

Intellia Therapeutics’s EPS estimate is -0.81.

How many shares outstanding does Intellia Therapeutics have?

Intellia Therapeutics has 115,829,926 shares outstanding.

What happened to Intellia Therapeutics’s price movement after its last earnings report?

Intellia Therapeutics reported an EPS of -€0.775 in its last earnings report, beating expectations of -€0.846. Following the earnings report the stock price went down -31.033%.

Which hedge fund is a major shareholder of Intellia Therapeutics?

Currently, no hedge funds are holding shares in DE:38I

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Intellia Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-52.11%

Trailing 12-Months

Asset Growth

-21.14%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Intellia Therapeutics

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Intellia Therapeutics (38I) Earnings & Revenues

Historic Earnings Reports

38I Revenue Breakdown

100.00% Collaboration revenue

38I Stock 12 Month Forecast

Average Price Target

€12.01

▼(-2.98% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","23":"€23","7.25":"€7.25","12.5":"€12.5","17.75":"€17.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22.73157783,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€22.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.011253470666665,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€12.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.36764116,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€3.37</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,7.25,12.5,17.75,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.458,8.632890602307693,9.807781204615384,10.982671806923076,12.157562409230769,13.332453011538462,14.507343613846153,15.682234216153846,16.857124818461536,18.032015420769227,19.20690602307692,20.381796625384617,21.556687227692308,{"y":22.73157783,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.458,7.808250266974359,8.158500533948718,8.508750800923076,8.859001067897434,9.209251334871794,9.559501601846152,9.90975186882051,10.26000213579487,10.61025240276923,10.960502669743589,11.310752936717947,11.661003203692307,{"y":12.011253470666665,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.458,7.143357012307693,6.828714024615385,6.514071036923077,6.19942804923077,5.884785061538462,5.570142073846154,5.255499086153846,4.940856098461539,4.626213110769231,4.3115701230769234,3.9969271353846154,3.682284147692308,{"y":3.36764116,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.06,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.952,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.234,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.19,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.522,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.752,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.384,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.485,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.458,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >